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Abstract X-ray structures of the GluR2 ligand-binding core in
complex with (S)-Des-Me-AMPA and in the presence and ab-
sence of zinc ions have been determined. (S)-Des-Me-AMPA,
which is devoid of a substituent in the 5-position of the isoxa-
zolol ring, only has limited interactions with the partly hydro-
phobic pocket of the ligand-binding site, and adopts an AMPA-
like binding mode. The structures, in comparison with other
agonist complex structures, disclose the relative importance of
the isoxazolol ring and of the substituent in the 5-position for
the mode of binding. A relationship appears to exist between the
extent of interaction of the ligand with the hydrophobic pocket
and the a⁄nity of the ligand.
) 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Glutamate mediates synaptic transmission between nerve
cells via binding to glutamate receptors (GluRs), and is re-
sponsible for most fast excitatory signaling within the mam-
malian central nervous system (CNS). The ionotropic GluRs
(iGluRs) form ligand-gated ion channels, and are divided
into three heterogeneous classes: 2-amino-3-(3-hydroxy-5-
methyl-4-isoxazolyl)propionic acid (AMPA), kainic acid, and
N-methyl-D-aspartic acid (NMDA) receptors [1]. The func-
tional iGluR is a tetramer composed of dimers-of-dimers
([2] and references therein). The iGluRs are involved in vari-
ous aspects of normal brain function, and are important for
the synaptic plasticity implicated in learning and memory for-
mation [3].
The two segments S1 and S2 have been shown to constitute
the ligand-binding core, to which the neurotransmitter is
bound (Fig. 1A). Previous studies have demonstrated that
the S1 and S2 segments are necessary and su⁄cient to obtain
a pharmacological pro¢le comparable to that of the full-
length membrane-bound receptor [4,5].
A recombinant, soluble form of the ligand-binding core of
the AMPA-receptor subunit GluR2 (GluR2-S1S2J) has been
produced by omitting the N- and C-terminal domains and by
substituting all transmembrane regions with a short hydro-
philic linker between the S1 and S2 segments [6,7]. Crystal
structures of the ligand-binding core of the apo form, of
one antagonist and several agonist complexes have been pub-
lished [6^8].
The ligands are bound in a cleft between two domains (D1
and D2), where D1 primarily is composed of segment S1, and
D2 primarily of segment S2 [6]. Comparison of the apo struc-
ture with the ligand-bound complexes has disclosed that bind-
ing of di¡erent ligands induces variable degrees of domain
closure. Interestingly, (S)-glutamate and (S)-AMPA adopt dif-
ferent binding modes [7]. However, AMPA analogues with
large 5-substituents at the isoxazole moiety as (S)-2-amino-
3-[3-hydroxy-5-(2-methyl-2H-tetrazol-5-yl)-4-isoxazolyl]propi-
onic acid ((S)-2-Me-Tet-AMPA) has been shown to adopt a
binding mode similar to that of glutamate [8].
In this study, the importance of the isoxazolol moiety, and
in particular the presence of a substituent at the 5-position,
has been investigated in relation to the mode of ligand bind-
ing. The AMPA analogue 2-amino-3-(3-hydroxy-4-isoxazo-
lyl)propionic acid (Des-Me-AMPA, Fig. 1B), which has a
hydrogen atom in the 5-position, shows relatively high
AMPA receptor a⁄nity (IC50 = 0.27WM for the racemate
[9]). Two high-resolution X-ray structures of GluR2-S1S2J
in complex with (S)-Des-Me-AMPA in the presence and ab-
sence of zinc ions are presented and are compared with other
agonist structures.
2. Materials and methods
2.1. Materials
(S)-Des-Me-AMPA was a kind gift from L. Brehm and B. Nielsen
(the asymmetric synthesis of the compound remains to be published).
The recombinant GluR2-S1S2J construct was expressed, refolded, and
puri¢ed essentially as reported [10].
2.2. Binding experiments
Ligand binding was performed as described previously [5]. Brie£y,
for saturation binding refolded GluR2-S1S2J protein (0.08 mg/ml)
was incubated for 1 h on ice with 1^200 nM [3H]AMPA (11.1 Ci/
mmol) in binding bu¡er (100 mM thiocyanate, 2.5 mM CaCl2, and 30
mM Tris^HCl, pH 7.2) to a total volume of 500 Wl. Competition
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experiments were performed under similar conditions, using 20 nM
[3H]AMPA and 0.02 nM^50 WM (S)-Des-Me-AMPA. Non-speci¢c
binding was determined in the presence of 1 mM glutamate. The
binding experiments were performed in triplicate.
2.3. Co-crystallization experiments
Crystallization was carried out at 6‡C using the hanging-drop vapor
di¡usion method. Protein and ligand were mixed at 6‡C 3^4 h prior to
crystallization experiments. The ¢nal mixture contained 8 mg/ml
GluR2-S1S2J and 3 mM (S)-Des-Me-AMPA in 10 mM HEPES,
pH 7.4, 20 mM NaCl, 1 mM EDTA, giving a molar ratio of 1:11.
Drops comprising 1 Wl protein^ligand solution and 1 Wl reservoir so-
lution were employed. Crystals were obtained both in the presence
and absence of zinc ions. The zinc-containing crystals were obtained
from a reservoir solution of 0.05 M Zn(OAc)2, 17% polyethylene
glycol (PEG) 8000, 0.1 M cacodylate, pH 6.5, whereas the zinc-free
crystals were obtained from a reservoir solution of 0.1 M Li2SO4, 20%
PEG8000, 0.1 M cacodylate, pH 5.2.
2.4. Data collection and processing
Crystals of GluR2-S1S2J in complex with (S)-Des-Me-AMPA were
£ash-cooled to 100 K using 18^20% glycerol added to the reservoir
solutions, as a cryoprotectant. Complete synchrotron data for the
zinc-free and for the zinc-containing crystals were collected at the
EMBL beamlines X11 and BW7B, DESY, Hamburg, equipped with
a MAR CCD and a MAR IP detector, respectively. Data processing
was performed using the HKL programs DENZO and SCALEPACK
[11], and the CCP4 suite of programs [12]. Statistics are listed in
Table 1.
2.5. Structure determination and re¢nement
Both structures were solved using the molecular replacement (MR)
approach, employing the program AMoRe [13] from CCP4. The zinc-
free complex was solved using the complex of GluR2-S1S2J and (S)-2-
Me-Tet-AMPA (protein atoms only) [8] as a search model. A clear
solution comprising three molecules was obtained. Subsequently, au-
tomated model building was performed with the program ARP/wARP
[14]. This resulted in the tracing of 94% of the residues, including a
fourth molecule which was not obtained with MR. The missing res-
idues were inserted by manual model building in the program O [15].
All three molecules in the zinc-containing structure were localized
with AMoRe using the zinc-free form as a search model. ARP/
wARP built 89% of the residues, and the remaining residues were
built manually. The structures were subjected to rebuilding in O
and re¢nements in CNS [16]. Ligand molecules, water molecules,
zinc ions, sulfate ions, and glycerol were gradually introduced into
the structures. Statistics are listed in Table 1.
The Fo^Fc electron densities for the ligand molecules were in all cases
very well de¢ned and the ligands were unambiguously modelled into it.
Initially, the ligand was geometry optimized with molecular mechanics
using the MMFFs force¢eld in Macromodel 7.2, including GB-SA
aqueous solvation [17]. Topology and parameter ¢les for the ligand,
used in CNS and in O, were generated by the HIC-Up server [18].
The HINGEFIND script [19], which is part of the programVMD
[20], was employed for analysis of domain closure. Figures were pre-
pared using the programs Molscript [21] and Raster3d [22].
2.6. Protein data bank accession numbers
The atomic coordinates and structure factor amplitudes of the
GluR2-S1S2J (S)-Des-Me-AMPA complexes have been deposited
with the RCSB Protein Data Bank (ID codes 1MQD and 1MS7).
3. Results and discussion
3.1. Characterization of GluR2-S1S2J
Saturation binding of [3H]AMPA and competitive displace-
ment of [3H]AMPA by (S)-Des-Me-AMPA was performed in
order to compare the pharmacology of the GluR2-S1S2J con-
struct with the pharmacology of the full-length receptor (Fig.
2). The pharmacological pro¢le of GluR2-S1S2J with an IC50
of 0.17 WM for (S)-Des-Me-AMPA is comparable to that of
the wildtype full-length GluR2 receptor (0.09 WM [StensbUl et
al., to be published]).
3.2. Interactions of (S)-Des-Me-AMPA with GluR2-S1S2J
The overall structure of the ligand-binding core of GluR2
has been described previously [6]. In this study, seven complex
molecules (MolA-C of the zinc-containing structure and
MolD-G of the zinc-free structure) have been built and re-
¢ned. All molecules form dimers in the crystal. MolA is used
as reference molecule throughout the text. The seven mole-
cules are very similar when superimposed on MolA (r.m.s.
di¡erence 0.27^0.37 AV on all CK atoms for MolC-G and
0.50 AV for MolB; for the latter, the largest di¡erences were
observed in loop 1 [6]). The other agonist complexes with (S)-
glutamate (MolA), (S)-AMPA (MolA) [7] and (S)-2-Me-Tet-
Fig. 1. A: The GluR2-S1S2J construct, comprising the ligand-bind-
ing core of the AMPA-receptor subunit GluR2, is composed of seg-
ments S1 and S2, joined by a linker (dashed line). The two domains
D1 and D2 are shown in yellow and green, respectively. The amino-
terminal domain is outlined as a red sphere, and integral membrane
parts are blue. B: The chemical structures of (S)-Des-Me-AMPA,
(S)-AMPA and (S)-2-Me-Tet-AMPA.
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AMPA (MolA) [8] used for comparison in this study super-
impose with r.m.s. di¡erences of 0.35^0.42 AV .
(S)-Des-Me-AMPA is observed to bind to the ligand-bind-
ing site in a very similar manner in all molecules. The inter-
actions between ligand and the ligand-binding core include
hydrogen bonds, ionic interactions and van der Waals inter-
actions (Fig. 3A, Table 2). The K-carboxylate group interacts
with Thr480 and Arg485 of D1, and with Ser654 of D2. Fur-
thermore, the K-carboxylate is at a hydrogen-bonding distance
to the water molecule W4 (water molecules are numbered ac-
cording to [8]). The K-ammonium group is positioned in a
tetrahedral network of interactions to Pro478 and Thr480 of
D1, and Glu705 in D2. This overall arrangement of the
K-amino acid part of the ligand is in accordance with the
previously reported agonist complex structures [6^8]. The
3-hydroxy group interacts with Thr655 from D2 and with
W2 and W4, which mediate indirect interactions to Leu650,
Ser654, Thr655 and Leu703. The isoxazole ring nitrogen is at
a hydrogen-bonding distance to Glu705 and to W3, which is
further connected to the side chains of Thr686 and Tyr702 in
D2.
3.3. The importance of the isoxazolol moiety and of the
5-substituent for ligand-binding mode
Until now, two modes of binding of an agonist to GluR2-
S1S2J have been observed, the so-called AMPA and gluta-
mate-binding modes [7,8]. The interactions of the 3-hydroxy
group in (S)-Des-Me-AMPA are similar to those observed in
the structure of the (S)-AMPA complex. Of special interest is
the presence of the water molecule W4, which has so far only
been observed in the AMPA structure, and which tethers the
agonist to the protein residues Ser654 and Thr655 (Fig. 3B).
In contrast, (S)-glutamate and (S)-2-Me-Tet-AMPA are lo-
cated at positions closer to D1 in the ligand-binding cleft. A
Q-carboxylate oxygen and a hydroxy oxygen, respectively, here
mimic the water molecule W4 observed in the (S)-AMPA
structure, and are able to make direct interactions to the
same protein residues.
As (S)-Des-Me-AMPA adopts the AMPA mode of binding
to the receptor, it may be concluded that it is the isoxazolol
Table 1
Crystal data, data collection, and re¢nement statistics
Crystals without zinc Crystals with zinc
Space group P2 P21212
Unit cell parameters (AV ,‡) a=105.4, b=47.5, c=123.9, L=113.7 a=113.7, b=162.9, c=47.1
Molecules/a.u. 4 3
Resolution range (AV )a 20^1.46 [1.49^1.46] 20^1.97 [2.02^1.97]
Unique re£ections 191 888 62 567
Average redundancy 3.9 5.2
Completeness (%) 99.0 [95.5] 99.5 [94.6]
Rmerge (%) 4.2 [38.4] 11.8 [65.2]
I/c(I) 26.7 [2.4] 12.1 [2.2]
Non-hydrogen atoms 10 796 7 287
Amino acid residues 1 032 774
Ligand/Zn2þ/glycerol/sulfate 4/0/1/3 3/6/0/0
Water molecules 2 651 1 187
Rwork (%) 18.0 19.1
Rfree; 2% (%) 19.2 21.2
r.m.s. bond lengths (AV )/angles (‡) 0.005/1.3 0.007/1.5
Residues in allowed regions of Ramachandran plot (%)b 99.8 99.6
Average B-values (AV 2) for protein/ligand atoms 15.9/11.5 21.3/20.1
aThe values in brackets correspond to the outermost resolution shell.
bThe Ramachandran plot was calculated according to Kleywegt and Jones [26].
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Fig. 2. Binding characteristics of the GluR2-S1S2J protein. A: Satu-
ration binding curve for [3H]AMPA. The calculated Kd is 18.1 nM
(W 4.6 nM) and Bmax is 1.66 pmol ( W 0.1). B: Displacement of
[3H]AMPA by (S)-Des-Me-AMPA. IC50 is 0.17 WM (0.086^0.354
WM).
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moiety, and not the 5-methyl group, which directs the binding
mode. However, AMPA analogues with larger 5-substituents
as (S)-2-Me-Tet-AMPA seem to favor the glutamate-binding
mode [8].
3.4. Met708 exerts an induced ¢t depending on the structure of
the bound agonist
By studying Fig. 3B, it is evident that the side chain of
Met708 from D2 adopts di¡erent conformations depending
on which ligand is bound. When a hydrogen atom is present
in the 5-position, as in (S)-Des-Me-AMPA, Met708 has an
extended side-chain conformation, to maximize the stabiliza-
tion of the ligand. Also in the (S)-AMPA structure, the con-
formation of Met708 is optimized for favorable van der Waals
interactions with the isoxazolol moiety and the 5-methyl sub-
stituent. In contrast, only weak stabilization by Met708 is
possible when glutamate is bound, as this agonist is located
in the upper part of the binding site. In the (S)-2-Me-Tet-
AMPA structure, Met708 adopts a conformation in which
the side chain partly points away from the 5-tetrazole ring,
thereby optimizing interactions with this ring. In this complex,
the backbone conformation around Met708 is also slightly
di¡erent from the other structures, pulling Met708 outwards.
This observation leads us to conclude that Met708 exerts an
induced ¢t, in order to maximize the van der Waals stabiliza-
tion of the bound ligand.
3.5. Relationship between the interaction with the partly
hydrophobic pocket and the a⁄nity of the ligand
A partly hydrophobic pocket exists in the ligand-binding
cleft of GluR2-S1S2J, which includes the above mentioned
Met708 [8]. The isoxazolol ring of (S)-Des-Me-AMPA is in-
volved in van der Waals interactions with Tyr450 and
Met708, while the presence of a methyl group in the 5-posi-
tion of the isoxazole ring of (S)-AMPA makes an additional
van der Waals interaction to Pro478 possible. (S)-2-Me-Tet-
AMPA, which has a large tetrazole ring in the 5-position, is
deeply imbedded in the pocket and is also in van der Waals
contact with Glu402 and Tyr405. However, the pocket is not
large enough to completely accommodate the tetrazole ring,
and this forces the ligand further up in the binding pocket to
adopt the glutamate-binding mode. Glutamate is not able to
interact with the hydrophobic pocket. Interestingly, there
seems to be a relationship between the extent of interaction
between the ligands and the hydrophobic pocket and the
a⁄nity (IC50) of the ligands: (S)-glutamate 0.50 WM [23] 6
(S)-Des-Me-AMPA (0.09 WM) 6 (S)-AMPA (0.02 WM) [23]
6 (S)-2-Me-Tet-AMPA (0.009 WM) [8].
Fig. 3. The ligand-binding site of GluR2-S1S2J. A: Interactions between GluR2-S1S2J and (S)-Des-Me-AMPA. Dashed lines indicate potential
hydrogen bonds/ionic interactions (up to 3.3 AV ). Water molecules are displayed as red spheres. Nitrogen atoms are shown in blue, oxygen
atoms in red, and sulfur atoms in dark green. B: Superimposition of the (S)-Des-Me-AMPA (cyan), (S)-AMPA (green), (S)-2-Me-Tet-AMPA
(magenta) and (S)-glutamate (yellow) complexes (shown in stereo). For all structures MolA is used as a representative. The conformation of
Met708 in the glutamate complex is unique for MolA, as the other two molecules have extended Met708 chains.
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3.6. The peptide £ip
Multiple conformations have been observed for the
Asp651^Ser652 peptide bond. The peptide bond is £ipped in
the structures of (S)-AMPA and (S)-2-Me-Tet-AMPA, com-
pared to the conformation observed in the apo, kainate, and
DNQX structures [6^8]. In the (S)-glutamate structure, this
peptide bond apparently exists in both conformations. A cor-
relation between peptide £ip and relative domain closure has
been suggested, as a large degree of closure (e.g. 21‡ for (S)-
AMPA relative to the apo structure) has been observed in
conjunction with a £ipped peptide bond, in contrast to less
closed structures (e.g. 12‡ in kainate).
However, in none of the seven molecules in the asymmetric
units of the two complexes with (S)-Des-Me-AMPA do the
electron densities indicate that the peptide bond between
Asp651 and Ser652 is £ipped, even though this ligand induces
almost the same domain closure as (S)-AMPA (19^21‡ for the
seven molecules). Thus, no clearcut correlation appears to be
present, and the importance of this feature remains to be ex-
plored. Neither of the residues Asp651 and Ser652 are in
direct contact with the ligands, but the surrounding residues
Leu650 and Ser654 make hydrogen bonds/van der Waals in-
teractions with the agonists.
3.7. The e¡ect of zinc and sulfate ions on the complex
The structure of GluR2-S1S2J was determined both in the
presence and in the absence of zinc ions, as it has previously
been observed that micromolar concentrations of zinc ions
can potentiate currents from native and recombinant recep-
tors [24,25].
Six zinc ions were identi¢ed in the zinc-containing complex,
coordinating all six His residues in the asymmetric unit. Five
zinc ions are located at interprotomer contact sites, while the
last one is coordinated by intraprotomer contacts. The zinc
ions only seem to induce small local changes in side-chain and
backbone conformations in this ligand complex, and the de-
gree of domain closure observed in the two structures is very
similar.
The ions coordinate to the following residues: Zn1 to
HisA412, HisB412, and GluB419; Zn2 to GluA431 and
HisA435; Zn3 to AspA454 and HisC412; Zn4 to GluB431,
HisB435 and GluC678; Zn5 to GluB678, GluC431 and
HisC435. Zn6 is located next to Zn5 and only coordinates
to water molecules. These interactions are similar to those
observed previously [7,8]. Three sulfate ions were located in
the zinc-free structure. SO41 coordinates to ArgB660, SO42 to
ArgA675, and SO43 to ArgA684, ArgD660, TrpD671 and
ArgD675. Also, these ions seem to induce only small, local
e¡ects.
4. Conclusions
This study leads us to conclude that: (1) The size of the
substituent in the 5-position of the isoxazolol ring is a major
determinant of the ligand-binding mode for AMPA-type ago-
nists. A large substituent results in a glutamate-like binding
mode, whereas small or no substituents leads to AMPA-like
binding. The isoxazolol moiety is not solely able to control the
binding mode. (2) A relationship appears to be present be-
tween the extent of interaction of the 5-substituent with a
partly hydrophobic pocket and the a⁄nity of the ligands.
(3) (S)-Des-Me-AMPA stabilizes a fully closed (21‡) confor-
Table 2
Hydrogen bonds and ionic interactions between (S)-Des-Me-AMPA and GluR2-S1S2J
(S)-Des-Me-AMPA (S)-Des-Me-AMPA (S)-AMPA (S)-2-Me-Tet-AMPA (S)-glutamate
Zn2þ present No Zn2þ present
MolA MolB MolC MolD MolE MolF MolG MolA MolA MolA
Carboxylate oxygen 1
Thr480 N 3.1 3.0 3.0 3.0 3.1 3.1 3.1 3.0 2.9 3.0
Arg485 NH1 2.9 2.9 2.8 2.7 2.7 2.7 2.7 2.8 2.8 2.8
Carboxylate oxygen 2
Arg485 NH2 3.0 3.0 3.1 2.9 3.0 2.9 2.9 3.0 2.8 2.9
Ser654 N 2.9 3.0 2.8 2.9 2.9 3.0 2.9 3.0 2.9 2.9
Ser654 OG 3.3 3.4 3.2 3.3 3.4 3.4 3.3 3.3 3.3 3.3
W4 3.1 3.0 3.0 3.1 3.2 3.1 3.1 2.9 ^ ^
Ammonium group
Pro478 O 2.9 2.9 2.6 2.9 2.9 2.9 2.9 2.7 3.0 2.7
Thr480 OG1 2.8 2.9 2.9 2.9 2.9 2.9 2.9 3.0 3.0 3.0
Glu705 OE1 2.5 2.5 2.6 2.7 2.7 2.7 2.7 2.7 2.7 2.7
Glu705 OE2 3.0 3.4 3.1 3.1 3.2 3.1 3.1 3.3 3.5 3.2
3-Hydroxy oxygen
Ser654 N ^ ^ ^ ^ ^ ^ ^ ^ 3.2 3.3a
Thr655 OG1 2.5 2.6 2.6 2.6 2.6 2.6 2.7 2.7 3.5 2.7b
Thr655 N ^ ^ ^ ^ ^ ^ ^ ^ 3.1 3.2a
W1 ^ ^ ^ ^ ^ ^ ^ ^ 2.8 3.1a
W2 2.9 2.8 3.1 3.0 2.9 2.9 2.9 3.0 ^ 3.0b
W4 2.3 2.4 2.3 2.5 2.6 2.6 2.6 2.5 ^ ^
W5 ^ ^ ^ ^ ^ ^ ^ ^ ^ 2.8b
Isoxazole ring nitrogen
Thr655 OG1 ^ ^ ^ ^ ^ ^ ^ ^ 2.8 ^
Glu705 N 3.1 3.1 3.2 3.3 3.2 3.2 3.2 3.1 ^ ^
W2 3.5 ^ ^ ^ ^ ^ ^ ^ 2.9 ^
W3 3.0 2.9 3.0 3.1 3.1 3.1 3.1 3.0 ^ ^
aContacts to Q-carboxylate oxygen 1.
bContacts to Q-carboxylate oxygen 2.
FEBS 26662 28-10-02 Cyaan Magenta Geel Zwart
C. Kasper et al./FEBS Letters 531 (2002) 173^178 177
mation without introduction of the Asp651^Ser652 peptide
£ip.
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